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Abstract 
The non-steroidal anti-inflammatory drug diclofenac is reported to cause, in rare cases, fulminant hepatic necrosis associated with 
chronic use of the drug. In order to investigate the possibility that covalent protein adducts of reactive metabolites of diclofenac might be 
responsible for the hepatotoxicity produced by this drug, we developed an antibody against a diclofenac-keyhole limpet hemocyanin 
adduct. The anti-diclofenac antibody did recognize diclofenac-protein adducts on Western blots of homogenates of cultured human 
hepatocytes exposed to diclofenac. The major detected adduct was a 60 kDa protein, which was present in both human and rat 
hepatocytes. These results suggest that binding of diclofenac to human hepatocytes is, like in rats, selective and that a 60 kDa protein 
appears to be the major target for alkylation. Immunoblots of homogenates of liver sinusoidal lining cells (LSLC) from rats treated with 
diclofenac also exhibited adducts with a 60 kDa protein. This fact suggest a role for LSLC in processing of chemically altered proteins in 
the liver. 
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1. Introduction 
Diclofenac is a non-steroidal anti-inflammatory agent 
that is usually prescribed for patients undergoing treatment 
for osteoarthritis, rheumatoid arthritis or ankylosing 
spondylitis. It is known that diclofenac can induce several 
types of hepatotoxicity. Diclofenac-induced direct toxicity 
has so far been considered uncommon, although mild 
increases in transaminases are well recognized [1,2]. The 
idiosyncratic reaction applies to a small number of patients 
who develop a severe form of hepatotoxicity that is fatal in 
some individual cases [3-121. The molecular basis of this 
reaction remains unknown. Some of the studies suggest a 
hypersensitivity basis for the toxicity [6,9-121, while oth- 
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ers favour a metabolic mechanism [3,5,7]. Both cases, 
however, could be attributed to the covalent modification 
of tissue proteins by reactive metabolites of diclofenac 
[13]. The metabolic mechanism of toxicity might be due to 
the alteration of a vital cellular function as a consequence 
of protein adduct formation. The hypersensitivity mecha- 
nism of toxicity might be due to an immune response 
against the covalent adducts (neoantigens) that at one stage 
might be presented in a MHC class I or class II restricted 
manner by antigen presenting cells, to competent cells of 
the immune system. In order to investigate this possibility, 
recently an anti-diclofenac anti-serum was developed for 
detecting adducts of diclofenac in liver homogenates of 
mice treated with diclofenac [14]. Radiochemical detection 
showed that diclofenac binds covalently to the proteins 
when incubates with cultured primary rat hepatocytes, 
depending on acyl glucuronide formation. A 60 kDa mi- 
crosomal membrane protein that accumulate in plasma 
membrane fraction, appears to be the major target of 
binding [15,16]. Using the immunochemical approach, it 
has been found that in rats glucuronide transferase cat- 
alyzed the formation of diclofenac metabolites that were 
bound selectively to hepatic plasma membrane proteins 
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(110, 140, 200 kDa and others) while cytochrome P-450 
monooxygenases catalyzed the formation of metabolites 
that were bound to a microsomal protein (50 kDa) [ 171. 
The aim of the present study was to determine whether 
hepatocellular proteins may be alkylated in humans by 
reactive metabolites of diclofenac, in spite of the relatively 
different biotransformation of the drug in animals and man 
[I 8,191. In this work, using Western blotting techniques, 
we have proved that diclofenac is bioactivated by human 
hepatocytes to reactive metabolites which covalently binds 
to hepatocellular proteins. The main protein target appears 
to be of an apparent molecular mass of 60 kDa. We have 
also characterized the diclofenac protein adducts in rat 
hepatocytes exposed to the drug. Finally, we found that the 
liver sinusoidal lining cell (LSLC) population, composed 
largely of Kupffer and endothelial cells, obtained from 
diclofenac-treated rats do carry the same major adduct 
detected in hepatocytes. This fact suggests an important 
role for LSLC in processing of chemically altered proteins 
in the liver. 
2. Materials and methods 
2. I. Chemicals 
Diclofenac sodium was purchased from Sigma (St. 
Louis, MO, USA). Keyhole limpet hemocyanin (KLH) and 
I-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydro- 
chloride (EDC) were purchased from Pierce (Rockford, IL, 
USA). Collagenase was from Boehringer-Mannheim 
(Mannheim, Germany). Calf serum was from Gibco (Pais- 
ley, UK) and culture media were from Flow (Irvine, UK). 
All other reagents used in this study were of analytical 
grade. 
2.2. Human and rat hepatocytes isolation, short-term cul- 
ture and exposure to diclofenac 
Human hepatocytes were obtained from small liver 
biopsies from patients undergoing cholecystectomy, after 
informed consent. The patients had not received any medi- 
cation for at least a week prior to surgery. Cell suspensions 
were obtained as described in detail elsewhere [20]. Rat 
hepatocytes were obtained from 200-300 g Sprague-Daw- 
ley male rats by perfusion of the liver with collagenase as 
described in detail elsewhere 1211. Hepatocytes were seeded 
on fibronectin coated culture plates (3.5 pug/cm*) at a 
density of 80 X lo3 cells/cm*. Unattached cells were 
removed by changing the medium one hour after seeding. 
Following 2 h adaptation of hepatocytes, cultures were 
incubated with different concentrations of diclofenac. After 
16 h, the hepatocytes were extensively washed with ice- 
cold PBS (pH 7.4). They were harvested by scrapping off 
the plate with a rubber policeman in ice-cold homogeniza- 
tion buffer (10 mM phosphate buffer, pH 7.4, 1 mM 
EDTA) and ultrasonicated. The homogenates were stored 
in aliquots at -80°C and typically thawed only once just 
prior to immunoblot analysis with diclofenac anti-sera. 
Protein concentrations in all experiments were estimated 
according to the method of Lowry et al. [22] with bovine 
serum albumin (BSA) as standard. 
2.3. Preparation qf liver sinusoidal lining cells from rats 
treated with diclofenac 
Sprague-Dawley male rats were administered a solu- 
tion of the sodium salt of diclofenac in saline at doses of 
50 and 100 mg/kg, by intraperitoneal injection. Control 
rats received only saline. After 16 h, liver cell suspensions 
were obtained by perfusion of the liver with collagenase as 
described [211. Cell suspensions were centrifuged for 4 
min at 30 X g, yielding a supematant fraction enriched in 
non-parenchymal cells. This fraction was applied in 
aliquots (10 ml) onto a pre-formed step gradient of Percoll 
comprising a lower and upper cushion (10 ml each) with a 
density of 1.066 g/ml and 1.037 g/ml, respectively. 
Gradients were centrifuged at 800 X g for 20 min. Cells 
were removed from the 1.066 g/ml cushion, washed and 
suspended in DMEM cultured medium. These cells were 
plated on plastic culture dishes at a density of 25 X 10’ 
cells/cm’. Cells were allowed to adhere for 20 min at 
37°C in a humidified atmosphere of 5% CO, and 95% air. 
After 20 min incubation, cells that did not adhere were 
removed through vigorous rinsing (2 X ) of the culture 
dishes with medium. Viability of adherent cells (by Trypan 
blue exclusion) was > 90%. This population, free of 
parenchymal cells, was composed of approx. 50% Kupffer 
cells (identified by peroxidase staining) and 50% of en- 
dothelial cells (peroxidase negatives) as reported [23]. 
They were harvested and homogenized as described for 
hepatocytes in Section 2.2. 
2.4. Preparation and detection of anti-diclofenac serum 
antibodies 
Diclofenac was covalently coupled to KLH by a two- 
step conjugation method [ 14,241. A methanolic solution of 
the sodium salt of diclofenac (0.3 mmol in 2.5 ml> was 
added to EDC (1.5 mmol in 7.5 ml of 20 mM sodium 
phosphate, pH 5.9). After 2 min, the reaction mixture was 
added to KLH (40 mg in 20 ml of 160 mM sodium 
phosphate, pH 8.01, and incubated overnight at room tem- 
perature. The conjugate was dialyzed against PBS. Di- 
clofenac was coupled to bovine serum albumin in a similar 
manner, except that 0.006 mmol of diclofenac was used 
for this reaction. 
New Zealand White rabbits were immunized subcuta- 
neously with 500 pug of the diclofenac-KLH conjugate 
emulsified in 1 ml of Freund’s complete adjuvant/PBS 
(1: 1). After 4 weeks, rabbits were boosted in a similar 
manner with 500 pg of conjugate in incomplete adjuvant, 
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and sera were collected after 12 days. The IgG fraction (pH 4.21, 2 mM H,O,) was added to the wells and the 
was purified and stored as described [25]. Titers were reaction was allowed to develop. Readings with a test 
maintained by booster injections of the immunogen every wavelength of 405 nm and a reference wavelength of 492 
2 months. nm were taken after 15, 30, and 60 min. 
Anti-diclofenac antibodies were determined by an en- 
zyme-linked immunosorbent assay (ELISA), with the use 
of diclofenac-BSA as the test antigen. Antigen (25 ng) 
diluted in 50 ~1 of 60 mM sodium carbonate (pH 9.6) was 
applied to the wells of microtiter plates. After overnight 
incubation at 4°C the wells were washed with 0.05% 
(v/v) Tween 20 in PBS (washing buffer). The wells were 
blocked with 50 ~1 of PBS containing 5% fetal calf serum 
(FCS), for 30 min at 37°C. Four washes with washing 
buffer were followed by the addition of 50 pi/well of 
anti-serum diluted in PBS 2% FCS and further incubation 
for 1 h a 37°C. The wells were washed four times. Goat 
anti rabbit horseradish peroxidase-conjugated (50 ~1) di- 
luted l/3000 in 2% FCS-PBS was added to the wells and 
incubated for 1 h a 37°C. After washing, 200 ~1 of the 
chromogenic solution (0.2 mM of 2,2’-azino-bis(3-ethylbe- 
nzthiazoline)sulfonic acid) (ABTS) in 0.15 M citrate buffer 
For the competitive inhibition experiments, ELISAs 
were performed as described above, except that the incuba- 
tion solution (anti-serum diluted l/3200) contained differ- 
ent concentrations of diclofenac. 
2.5. Immunoblotting procedure 
Proteins from cellular homogenates were separated by 
SDS-PAGE according to the method of Laemmli [26] 
using a 12.5% separating gel and transferred electrophoret- 
ically to a polyvinylidene difluoride membrane (PVDF, 
Millipore). The membrane was blocked for 1 h with 10% 
(w/v) milk powder in PBS (pH 7.4). The blot was washed 
with washing buffer (0.05% v/v Tween 20 in PBS) and 
incubated with the anti-diclofenac anti-serum diluted 
l/2000 in 3% (w/v) milk powder in washing buffer for 
16 h at room temperature under constant shaking. After 
washing, the membrane was incubated with goat anti 
rabbit horseradish peroxidase-conjugated diluted l/20000 
for 1 h. After the corresponding washing, labelled proteins 
were detected using the enhanced chemiluminescence de- 
tection system (ECL, Amersham) according to the manu- 
factures guidelines. In all experiments, apparent molecular 
weights of antigenic polypeptides were estimated by com- 
paring their relative mobilities to that of marker proteins of 
known molecular weight. 
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Fig. 1. (A) Detection by ELISA of antibodies raised against diclofenac- 
protein adduct. Wells were coated with either 25 ng of diclofenac-BSA 
conjugate ( ??) or native BSA ( 0 ). Serum III from a rabbit immunized 
with diclofenac-KLH was partially purified, serially diluted and added to 
the wells. Peroxidase activity is expressed as absorbance COD) per 1 h. 
(B) Competitive inhibition of binding of anti-diclofenac antibodies to 
solid-phase diclofenac-BSA conjugate, by the indicated concentrations of 
diclofenac. 
3. Results 
3. I. Generation of anti-diclofenac rabbit anti-sera 
To detect the presence of antibodies in sera of rabbits. 
immunized with diclofenac-KLH adduct, the sera were 
tested by ELISA against both the diclofenac-BSA conju- 
gate and BSA alone. Three different reactive sera from 
rabbits I, II and III were obtained with identical anti-di- 
clofenac activity tested by ELISA. Fig. 1A shows the 
reactivity of serum III like example. The results demon- 
strate that the antibodies reacted with the solid phase 
antigen of diclofenac coupled to BSA, whereas BSA alone 
was not antigenic. In a competitive ELISA (Fig. 1B) 
diclofenac was effective as inhibitor of the reaction of the 
antibodies with diclofenac-BSA (60% inhibition at 1 mM 
concentration). This behaviour demonstrates the specificity 
of the anti-diclofenac antibody. 
3.2. Immunochemical analysis of human hepatocyte pro- 
teins after exposure of cultured cells to diclofenac 
In order to investigate whether hepatocellular proteins 
may be alkylated in humans, we obtained homogenates of 
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Fig. 2. Western blot analysis of diclofenac-protein adducts in homogenates of cultured human hepatocytes exposed to diclofenac. 16 h after treatment of 
the cells from biopsy number I (A) and biopsy number 2 (B,C), with vehicle only, 300, 400 and 500 PM diclofenac (lanes 1-4 respectively), the proteins 
were resolved by SDS-PAGE (30 I.c.g/lane), transferred to PVDF membranes and probed with anti-diclofenac antisera III (A,B) and I (Cl. Position of 
standard proteins of known molecular mass (in kDa) are indicated. Arrows indicate the 60 kDa species, 
cultured human hepatocytes from two different small liver lar mass of 60 kDa is the major target detected in both 
biopsies (biopsies 1 and 21, exposed to increasing concen- biopsies tested and by the two sera utilized. 
trations of diclofenac (300, 400 and 500 PM). Immuno- In biopsy 2, other additional minor proteins (5.5 and 70 
blotting studies, using the diclofenac anti-sera I and III are kDa) were also recognized (Fig. 2B,C) by the two anti-sera 
shown in Fig. 2. The results demonstrate that diclofenac (I and III). The intensity of binding in biopsy 2 increased 
binding to proteins in human hepatocytes occurred in a in a dose-dependent manner. On the other hand, in biopsy 
selective manner and that a protein with apparent molecu- 1 the binding was to several proteins and appeared to reach 
A 
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B C 






Fig. 3. Western blot analysis of diclofenac-protein adducts in homogenates of cultured rat hepatocytes exposed to diclofenac. I6 h after treatment of the 
cells with vehicle only, 100, 200 and 300 FM diclofenac (lanes l-4, respectively), the proteins were resolved by SDS-PAGE (50 pg/lane), transferred to 
PVDF membranes, and probed with anti-diclofenac anti-sera 1 (A), II (B) and III (Cl. Molecular weights &Da) of standard proteins are listed to the left of 
panels A and C. Arrows indicate the 60 kDa species. 
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the maximal intensity at 300 PM (Fig. 2A). We also 
observed that in control hepatocytes (Fig. 2A-C, lanes 11, 
the anti-diclofenac sera recognized different non di- 
clofenac-labelled polypeptides. 
3.3. Immunochemical analysis of proteins after exposure of 
rat hepatocytes to diclofenac 
Diclofenac-protein adducts were detected using anti-di- 
clofenac antibodies in Western-blot analysis of ho- 
mogenates of cultured rat hepatocytes exposed to increas- 
ing concentrations of the drug (100, 200 and 300 PM). 
Fig. 3 shows the results obtained with diclofenac anti-sera 
I, II and III, which recognized several polypeptides in 
hepatocytes exposed to diclofenac that were not recog- 
nized in control hepatocytes. A protein or protein subunit 
with apparent molecular mass of 60 kDa constitute the 
major target. Additional minor proteins were recognized 
by the anti-diclofenac antibodies, i.e., a 30 kDa protein by 
the three sera tested, and 44, 46 and 70 kDa by the sera I 
and II. Like in human hepatocytes, the diclofenac anti-sera 
detected different polypeptides in rat hepatocytes not ex- 
posed to the drug. 
3.4. Immunochemical detection of diclofenac adducts in 
liver sinusoidal lining cells of rats treated with diclofenac 
Previous investigators have demonstrated that LSLC 
can function as antigen presenting cells (APC) after anti- 
gen exposure ‘in vivo’ [23]. We have speculated that in the 
liver, these populations of cells, might be involved in 
processing and presenting of diclofenac adducts. In order 
106 - 
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Fig. 4. Western blot analysis of diclofenac-protein adducts in ho- 
mogenates of LSLC from diclofenac-treated rats. LSLC from saline- 
treated control rats (lane 1) or from rats injected intraperitoneally with 50 
and 100 mg/kg diclofenac (lanes 2 and 3, respectively), were homoge- 
nized and probed by immunoblot with anti-diclofenac anti-serum III. The 
protein size markers are indicated in kilodaltons. Arrows indicate the 60 
kDa species. 
to investigate this hypothesis, the first step was to prove 
whether or not these cells actually do carry adducts di- 
clofenac-protein. 
Rats were administered saline or diclofenac intraperi- 
toneally (50 and 100 mg/kg). After 16 h, we obtained the 
population of LSLC and these cells were harvested and 
homogenized. Immunoblot analysis of LSLC homogenates 
from the treated rats, but not from control rats, revealed 
that the anti-diclofenac antibodies recognized one adduct 
with apparent molecular mass of 60 kDa (Fig. 4). Based on 
apparent molecular weight, this adduct might be the same 
major adduct detected in rat and human hepatocytes. 
4. Discussion 
Covalent binding of the drug metabolites to cellular 
proteins is the primary mechanism either in direct drug 
toxicity or in drug-induced allergic hepatitis. In the present 
study, using an immunochemical approach, we have shown 
that diclofenac selectively binds to proteins or proteins 
subunits in cultured human hepatocytes and that the LSLC 
from rats treated with diclofenac do carry an immuno- 
reactive protein of similar molecular weight that the adduct 
detected in rat and human hepatocytes. 
We first obtained an anti-sera raised against a di- 
clofenac-KLH adduct and developed an ELISA test which 
enabled us to show that diclofenac was able to inhibit in 
part the reaction of the anti-sera with BSA-diclofenac. This 
fact suggests that the antibodies could react with all possi- 
ble covalent adducts of diclofenac that retained structural 
features of the diclofenac molecule [27]. 
In order to investigate the possibility that diclofenac- 
protein adducts might have a role in the hepatotoxicity 
produced by diclofenac in man, it seems of interest to 
determine whether hepatocellular proteins may be targeted 
in human hepatocytes. We exposed human hepatocytes to 
high doses of diclofenac (300, 400 and 500 PM) in 
accordance with the recently published study of Kretz- 
Rommel and Boelsterli [ 153, who demonstrated that di- 
clofenac covalent binding is dependent on acyl glu- 
curonide formation in rats, and knowing that in human 
liver there are low rates of acyl glucuronide formation [ 181. 
In fact, the immunoblot analysis revealed that diclofenac 
binds to proteins in human cultured hepatocytes. The most 
prominent adduct was associated with the protein of 60 
kDa in both biopsies tested. The intensity of the signal was 
very high even at the lowest dose tested. The number of 
additional minor adducts increased with high concentra- 
tions of diclofenac in biopsy 1. However, in biopsy 2 does 
not change, reflecting the individual variations in rates of 
drug biotransformation. This indicates that different pro- 
teins may be targeted progressively with increasing drug 
concentrations. 
Our results have established that the diclofenac-protein 
adducts expressed in cultured human hepatocytes are not 
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noticeably different from the adducts expressed in cultured 
rat hepatocytes. On using rat hepatocytes, a 60 kDa protein 
was the major target of binding detected by the three sera 
used. This result is in agreement with the previous study of 
Kretz-Rommel and Boelsterli [16]. The anti-sera recog- 
nized also additional minor proteins (30, 44, 46 and 70 
kDa1. However, additional adducts of 50, 80 and 126 kDa 
were detected by Kretz-Rommel and Boelsterli [16]. This 
discrepancy may be due to differences in anti-sera speci- 
ficities. The differences between the results of Kretz-Rom- 
me1 and Boelsterli [ 161 and those of Hargus et al. [ 171, in 
the studies in rats ‘in vivo’, have been also explained by 
the differences in anti-sera specificities. It is unlikely that 
the proteins recognized by the anti-sera in hepatocytes 
exposed to diclofenac represent native epitopes and are 
unrelated to drug bioactivation because they were not 
detected in cells that were not exposed to diclofenac. It is 
not unreasonable to suggest that the low molecular mass 
proteins may represent subunits or degradation products. 
The diclofenac anti-sera contained antibodies which 
recognize different proteins in hepatocytes not exposed to 
diclofenac, depending on the anti-sera and the species of 
hepatocytes (human or rat). Similar results have been 
obtained in the case of halothane, a drug that is associated 
with immune-mediated liver injury in humans [28-301. 
The significance of the antibodies that recognize a variety 
of non diclofenac-modified liver polypeptides, in the pre- 
sent study, is unclear at the present time. 
In view of our results, we feel that isolated human 
hepatocytes are a suitable model for more detailed investi- 
gation of the mechanisms that underly the formation and 
processing of the diclofenac-protein adducts in man. 
The detection in LSLC of rats treated with diclofenac of 
a major diclofenac-protein adduct of similar molecular 
weight that the adduct detected in hepatocytes, point to the 
possibility that these adducts have the same cellular origin. 
Hepatocytes would be expected to be mostly responsible 
for drug metabolism; the question arises then how LSLC 
could acquire the adducts. The presence of protein adducts 
of reactive metabolites of halothane have also been de- 
tected in Kupffer cells [31]. Clearly, further experimenta- 
tion will be needed to clarify the mechanisms by which 
these cells acquire the adducts. Alkylation tags hepatocytes 
for phagocytic uptake by Kupffer cells, therefore, adducts 
found are transferred from hepatocytes or LSLC have the 
capacity of metabolizing diclofenac and consequently, the 
adducts are arising from within LSLC? This last possibility 
is corroborated by studies that have revealed that drug- 
metabolizing enzymes are not restricted to liver parenchy- 
ma1 cells [32]. 
Overall, our results have established, for the first time, 
that binding of diclofenac to human hepatocytes is selec- 
tive and that a 60 kDa protein appears to be the major 
target for alkylation. We also established that the LSLC 
population (endothelial and Kupffer cells) obtained from 
diclofenac treated rats do carry an adduct of similar molec- 
ular weight that the adduct detected in hepatocytes, sug- 
gesting a role for LSLC in processing of chemically 
altered proteins in the liver. It remains for the future, the 
identification of the proteins targeted by diclofenac, the 
demonstration of the adducts in patients and the clarifica- 
tion of the role of LSLC in diclofenac hepatitis. 
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